| DC7303 |
NVP-TAE684
Featured
|
NVP-TAE684(TAE684) is a highly potent and selective small-molecule ALK inhibitor, which blocked the growth of ALCL-derived and ALK-dependent cell lines with IC50 values between 2 and 10 nM. |
|
| DC8463 |
NVP-TNKS656
Featured
|
NVP-TNKS656(TNKS-656) is a highly potent, selective, and orally active TNKS2 inhibitor with IC50 of 6 nM; > 300 fold selectivity against PARP1 and PARP2. |
|
| DC12583 |
NVR 3-778
Featured
|
NVR 3-778 (NVR3-778, NVR 3778) is a small molecule inhibitor of HBV replication that targets the viral core protein, a first-in-class capsid assembly modulator. |
|
| DC24111 |
NVS-CRF38 |
NVS-CRF38 is a potent, selective, orally bioavailable corticotropin-releasing factor receptor 1 (CRF1) antagonist with IC50 of 70 nM.. |
|
| DC10473 |
NVS-PAK1-1
Featured
|
NVS-PAK1-1 potently inhibits autophosphorylation of PAK1 (S144) at 0.25 µM in the Su86.86 cell line and MEK S289 phosphorylation with an IC50 = 0.21 in Su86.86 cells in which PAK2 is downregulated. |
|
| DC21431 |
NXL101 |
NXL101 is a novel quinoline bacterial DNA gyrase and topoisomerase IV inhibitor that shows potent activity against gram-positive bacteria, including methicillin- and fluoroquinolone-resistant strains. |
|
| DC4237 |
NXY-059 (Cerovive) |
NXY-059 (Cerovive) is an EGFR and HER2 autophosphorylation inhibitor, against purified EGFR and HER2 of 10.2 and 9.8 nM, respectively. |
|
| DC12712 |
NY0116 |
NY0116 (NY 0116) is a small molecule neuromedin U receptor 2 (NMUR2) with EC50 of 27.76 uM for hNMUR1 and 13.61 uM for hNMUR2 in intracellular calcium mobilization assays. |
|
| DC21432 |
NY-0123 |
NY-0123 is a novel potent Exchange proteins directly activated by cAMP (EPAC) antagonist with IC50 of 0.9 and 2.4 uM for EPAC1 and EPAC2, respectively. |
|
| DC12713 |
NY0128 |
NY0128 (NY 0128) is a small molecule neuromedin U receptor 2 (NMUR2) with EC50 of 29.99 uM for hNMUR1 and 10.30 uM for hNMUR2 in intracellular calcium mobilization assays. |
|
| DC21433 |
NY-0173 |
NY-0173 is a potent Exchange proteins directly activated by cAMP (EPAC) inhibitor with IC50 of 4.0 uM for EPAC1.. |
|
| DC11382 |
NYX-2925
Featured
|
NYX-2925 is a Novel NMDA Receptor-Specific Spirocyclic-β-Lactam That Modulates Synaptic Plasticity Processes Associated with Learning and Memory. |
|
| DC22185 |
O-1602 |
O-1602 (O1602) is an atypical cannabinoid, potent and selective agonist of GPR55 cannabinoid receptor with EC50 of 13 nM, shows no significant activity for CB1 and CB2 receptors (EC50>30 uM). |
|
| DC10807 |
O304
Featured
|
O304 is a novel AMPK activator. |
|
| DC8346 |
O4I-1
Featured
|
O4I1-1 is a Oct3/4 inducer. Increases Oct3/4 mRNA levels in HEK293 cells by 2.5- and 4-fold at 10 μM and 20 μM, respectively. |
|
| DC8345 |
O4I2
Featured
|
O4I2 is a a new class of small molecules suitable for iPSC generation, showed high activity in enforcing Oct3/4 expression. |
|
| DC8208 |
OAC1
Featured
|
OAC1 is a Octamer-binding transcription factor 4 (Oct4)-activating compound; enhances the iPSC reprogramming efficiency and accelerated the reprogramming process. |
|
| DC8273 |
OAC2
Featured
|
OAC2 is an Oct4-activating compound which activates expression through the Oct4 gene promoter; enhances reprogramming efficiency by increasing the rate of production of induced pluripotent stem cells (iPSCs) from embryonic fibroblasts; an analog of OAC1. |
|
| DC20481 |
OADS |
OADS is a specific, reversible, small-molecule inhibitor directs against CLC (Chloride Channel) antiporter with Ki of 29 uM, has no specific effect on a CLC channel (ClC-1). . |
|
| DC21435 |
OAT-1746 |
OAT-1746 is a novel potent, selective, orally active inhibitors of Arginase 1 and 2 (ARG1/2) with IC50 of <50 nM. |
|
| DC21436 |
OAT-177
Featured
|
OAT-177 is a potent, selective, orally active acidic mammalian chitinase (AMCase) inhibitor with IC50 of 14 and 19 nM against human and mouse AMCas, respectively, >150-fold selectivity over mCHIT1. |
|
| DC21437 |
OAT-2068
Featured
|
OAT-2068 is a potent, selective, orally bioavailable inhibitor of mouse chitotriosidase (mCHIT1) with IC50 of 29 nM, 143-fold selectivity over mAMCase. |
|
| DC25107 |
OBA-09 |
OBA-09 is a simple ester of pyruvate and salicylic acid, main metabolites of pyruvate and aspirin, respectively, exerts robust neuroprotective effect in the postischemic brain in vivo. |
|
| DC7217 |
Obatoclax (GX15-070)
Featured
|
Obatoclax (GX15-070) is Bcl-2 homology domain-3 (BH3) mimetic, antagonize all antiapoptotic Bcl-2 family proteins (average IC50, 3 umol/L), including Mcl-1 (IC50, 2.9 umol/L) and Bfl-1 (IC50, 5 umol/L). |
|
| DC23421 |
OBE022 |
OBE022 is a potent, highly selective, orally active antagonist of the contractile PGF2α prostaglandin receptor with Kb of 5.9 nM, shows no activity for other human PG receptors subtypes. |
|
| DC10134 |
Obicetrapib (AMG-899,TA-8995)
Featured
|
Obicetrapib is a CETP inhibitor, on the elevation of high-density lipoprotein cholesterol (HDL-C) and reduction of low-density lipoprotein cholesterol (LDL-C), alone and in combination with statin therapy. |
|
| DC21438 |
OBP-801 |
OBP-801 (YM 753;Spiruchostatin A) is a novel cyclic-peptide-based HDAC inhibitor with IC50 of 2 nM. |
|
| DC1026 |
OC000459(Timapiprant)
Featured
|
OC000459, a Potent, Selective, and Orally Active D Prostanoid Receptor 2 Antagonist. |
|
| DC10144 |
Ochratoxin A(OTA)
Featured
|
Ochratoxin A demonstrates nephrotoxicity and teratogenesis in animals, and shows inhibition of bacterial, yeast, and liver FARSL (phenylalanyl-tRNA synthetases) competitive with phenylalanine. |
|
| DC10145 |
Ochratoxin B(OTB)
Featured
|
Ochratoxin B(OTB) is a non-chlorinated analog of OTA that has cytotoxic effects on kidney and liver cells in vitro but only minor effects in vivo, due to its rapid metabolism and excretion. |
|
